/
PCVX
$58.84+$1.12 (+1.94%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$8.2B
144M shares
52-week range
$29.08 – $65.00
83% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.28%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$35.88
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.0M | $1.2M | $1.4M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$1.0M | −$1.2M | −$1.4M | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $30.1M | $45.6M | $73.6M | $78.4M | $169.5M | $332.3M | $476.6M | $794.3M |
| Operating income | −$35.5M | −$54.2M | −$89.6M | −$103.7M | −$232.3M | −$468.0M | −$569.5M | −$923.7M |
| EBITDA | −$28.4M | −$49.0M | −$87.8M | −$96.6M | −$214.0M | −$392.1M | −$448.1M | −$741.8M |
| Net income | −$29.5M | −$50.3M | −$89.2M | −$100.1M | −$223.5M | −$402.3M | −$463.9M | −$766.6M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -8.12 | -14.10 | -2.97 | -1.93 | -3.44 | -4.14 | -3.80 | -5.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25M | $-8.38 | $-9.89–$-6.59 | 6 |
| 2027 | $87M | $-6.69 | $-7.90–$-5.38 | 6 |
| 2028 | $177M | $-6.36 | $-10.99–$-4.60 | 6 |
| 2029 | $1.5B | $1.00 | $1.00–$1.00 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Vaxcyte, Inc. Common Stock
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
www.vaxcyte.com- Employees
- 507
- IPO / List date
- Jun 12, 2020
- HQ
- SAN CARLOS, CA
Held by traders on TradeandTell
No one on the platform currently holds PCVX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 54,734 | $3.2M |
| Bridgewater Associatesas of 2026-03-31 | 12,903 | $749.8K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PCVX yet.
